An official ATS statement: hepatotoxicity of antituberculosis therapy. - Wikidata - awgldk - TriplyDB

An official ATS statement: hepatotoxicity of antituberculosis therapy.

An official ATS statement: hepatotoxicity of antituberculosis therapy.

http://www.wikidata.org/entity/Q34571651

about

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB Challenges in the diagnosis & treatment of miliary tuberculosis Recent developments in treatment of latent tuberculosis infection Drug-Induced Liver Toxicity and Prevention by Herbal Antioxidants: An Overview Hepatic manifestations of non-steroidal inflammatory bowel disease therapy Treatment of Drug Susceptible Pulmonary Tuberculosis Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium Challenging issues in tuberculosis in solid organ transplantation PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2 Hepatotoxicity from antituberculous therapy in the elderly: a systematic review Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps Transgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicity Assessment of treatment response in tuberculosis Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1 Tuberculosis and hepatic steatosis are prevalent liver pathology findings among HIV-infected patients in South Africa Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study Cost Resulting from Anti-Tuberculosis Drug Shortages in the United States: A Hypothetical Cohort Study Wild Edible Fruit of Prunus nepalensis Ser. (Steud), a Potential Source of Antioxidants, Ameliorates Iron Overload-Induced Hepatotoxicity and Liver Fibrosis in Mice Predictors of Prolonged TB Treatment in a Dutch Outpatient Setting Toxicity study of Lauha Bhasma (calcined iron) in albino rats Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue?Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data.Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis Antitubercular therapy in patients with cirrhosis: challenges and options Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004.Hepatotoxicity Due to Antituberculosis Therapy among Paediatric Patients Seen at the University of Ilorin Teaching Hospital, North Central Nigeria.Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.Clinical review: tuberculosis on the intensive care unit.Risk for latent and active tuberculosis in Germany.Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999-2013

P2860

Q21245662-79530800-2785-4833-A1CE-F7A1AC189F83 Q24630463-B0886E72-286B-4C99-8C1E-FEC967421EA3 Q24630473-42DA74EE-7E36-4C3D-938D-8BAAD7E857B2 Q26767516-51BD7326-9582-413A-BCEA-1BDB29E6AA27 Q26773684-5E1F6F6D-2315-40B6-B84E-3460D74B4B64 Q26801605-107EC566-6E27-438F-A81F-5D32FA40191B Q26865560-70532A33-E088-42A6-895F-0FF37BDF786B Q26998877-5B85DFCF-AEF6-4C93-B6E3-5198B769386C Q27011622-53A94D37-7ED3-4369-BF0A-5F5EED957FF5 Q27022370-B1C0FFFA-063B-46D7-B4CA-C83038FD0793 Q27022592-F2214610-2578-4EF3-9933-6C8B26276BA1 Q28087473-D23083B3-B345-48BA-A9D6-08D8F1A6204B Q28384421-83CC1F9A-93C2-4D97-B326-88E8DF2E67B5 Q28478275-F3156922-2B14-4B55-9719-B1B74E973003 Q28478918-F5A3A9DA-6F26-4AEB-B4F6-9CAC627AE02C Q28478920-2DF1FF72-97EC-4741-ADBC-98868BEF70BA Q28479103-7ACE94D9-08AA-4C82-8C0F-94C196D4576F Q28481272-6B924FCC-0C49-497F-9784-CFD7F7F11912 Q28484468-9A8D6D2B-6B9B-43D0-83C9-F4B0F1AEDB97 Q28486869-DD4CEC78-7AB3-495A-BC2C-77CFE47621C6 Q28533930-3977ECD3-DC94-4F2C-BEFA-EAE058E7CDFD Q28539060-467F459F-EA46-4FE8-B229-5AAF206E04E4 Q28543376-538F423C-3D3C-4663-B9E8-7F368F8EC320 Q28544718-5A0702F7-F6B2-4884-A93E-1E5BBB1262BA Q28547335-52FA77CB-1B22-417D-9317-6557349C4416 Q28551313-F2BA8088-40C5-4D42-837D-A7C5B910A1F6 Q28553471-F25D99A2-DE4F-4924-8C4A-676DE76257A9 Q28603559-C4B39C83-6DF2-471A-B8E4-F091BC0CF263 Q30241648-D55793B5-4A72-4BCE-B779-7E9FBBF8FB13 Q30277969-37A8F70E-3017-45B4-B816-096F7E851B40 Q30498213-AADB65D9-E02A-4297-8B53-CA770FD1A967 Q30582650-AB9D43CD-FF72-46F2-A6B9-31A4F12E5C54 Q33532816-FBF36D72-9098-479C-B0FC-0952430FE3B6 Q33626827-7010B7A5-2254-42FC-854E-9BF91F48A688 Q33662605-E31FFAAC-6312-4A3A-AEA8-04D9AA20116F Q33716365-309D2979-5D32-4369-BDB7-77CF765F8D26 Q33746114-CF4A8E5F-21E0-4312-A279-00032A7B82E0 Q33750370-27D75AB5-64E8-4BB1-8CDD-0698EB613B3E Q33845283-46BCAAE5-6B1F-42CB-8F42-05009B37BEE8 Q33867704-EC2505B1-4F5D-4938-8F89-8F1ECCF49D93

P2860

An official ATS statement: hepatotoxicity of antituberculosis therapy.

http://www.wikidata.org/entity/Q34571651

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@ast

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@en

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@nl

type

label

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@ast

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@en

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@nl

prefLabel

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@ast

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@en

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@nl

P1433

Q34571651-1C0098BC-FEF4-4FCC-BD80-31D228F11474

P1476

Q34571651-4D1BE9ED-8BA5-4269-8FEE-AE2A6E63F5BA

P2093

Q34571651-03C27967-34EB-4F99-B83B-7ED54DD2E137

Q34571651-184AC7E3-414B-41A5-8145-9FE1A880A4C2

Q34571651-1EDED0B0-DE46-48A9-8771-A060930C2EC1

Q34571651-28C9E4EF-AB9D-4B16-B642-734514D83223

Q34571651-547A3624-26D2-480A-9292-97AB11B50306

Q34571651-75013B94-CD17-4E2F-A038-7EEBA4F44B6C

Q34571651-75060B6E-AB32-41DE-A6CB-275C147893B3

Q34571651-A961944A-855E-4898-A126-B42696F79109

Q34571651-A9F54267-7992-406C-BBDE-9E8F91A4A842

Q34571651-C0D4F2CA-8902-4EE3-B425-F25188AAB2C6

P304

Q34571651-7FEF8B7F-042A-4E28-94C0-D61FDC60B400

P31

Q34571651-39CB9EB2-2A16-48A3-9AF9-601E1D2D9BC8

P356

Q34571651-661EE35E-FE22-4ACF-868F-237124CFCD04

P407

Q34571651-4B6B0C88-4BF3-4427-90F0-0088C9DEB832

P433

Q34571651-95CB7349-FA55-4752-BAA8-684650150522

P478

Q34571651-C99FD0C8-F590-433F-8CC2-5683E80D327A

P577

Q34571651-2049F944-1871-4DDC-85F5-77375A57827F

P698

Q34571651-FC7499A8-5246-47F2-9711-FC8231D69D70

P921

Q34571651-2E9071FD-65F6-4213-83F1-E2999E778E52

P356

RCCM.200510-1666ST

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

An official ATS statement: hepatotoxicity of antituberculosis therapy.

@en

P2093

ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee

http://www.w3.org/2001/XMLSchema#string

Charles A Peloquin

http://www.w3.org/2001/XMLSchema#string

Charles M Nolan

http://www.w3.org/2001/XMLSchema#string

David L Cohn

http://www.w3.org/2001/XMLSchema#string

David Nunes

http://www.w3.org/2001/XMLSchema#string

Dorothy B Strader

http://www.w3.org/2001/XMLSchema#string

Fred M Gordin

http://www.w3.org/2001/XMLSchema#string

John A Jereb

http://www.w3.org/2001/XMLSchema#string

John Bernardo

http://www.w3.org/2001/XMLSchema#string

Jussi J Saukkonen

http://www.w3.org/2001/XMLSchema#string

P304

935-952

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200510-1666ST

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

174

http://www.w3.org/2001/XMLSchema#string

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17021358

http://www.w3.org/2001/XMLSchema#string

P921